Moosa Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Moosa Patel has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Vinitha Philip
Clinical Haematology Unit, Department of Medicine, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
7 shared publicationsAtul Lakha
Clinical Haematology Unit, Department of Medicine, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
6 shared publications- Paul Ruff
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5 shared publications - Freddy Sitas
UNSW
4 shared publications - Martin Hale
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
4 shared publications - Margaret Urban
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa
3 shared publications
Latest Publications
- Open Access
- 11 April 2025
- Published by AOSIS in South African Journal of Oncology
- Vol. 9, 8
Autologous stem cell transplantation in multiple myeloma at Chris Hani Baragwanath Academic Hospital
Background: Autologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma (MM), even in the era of novel therapeutic agents. Data regarding ASCT outcomes in MM is lacking in South Africa. Aim: To assess the impact of ASCT on MM at a public health facility. Setting: Clinical Haematology Unit, Chris Hani Baragwanath Academic Hospital, Johannesburg. Methods: A retrospective analysis of MM patients who received ASCT over 19 years. Results: Fifty-one patients received ASCT as part of their treatment schedule. While 41 patients received a single transplantation, 10 patients underwent a salvage transplantation after relapsing. Most of the patients (74.5%) had a delayed transplantation. The median overall survival (OS) was 57 months for the entire group, 32 months in the early transplantation group and 58.5 months in the delayed transplantation group, with no statistical difference between the early and delayed groups (p = 0.12) and among the different International Staging System groups (p = 0.71). The median time for disease relapse after the first ASCT was 30 months. Conclusion: Autologous stem cell transplantation is an important consolidation treatment modality for MM in the South African public health sector as it prolongs survival. Greater access to novel agents during induction and relapse is advocated in the South African public health sector to further improve the outcomes that are currently seen with ASCT. Contribution: This study adds to the limited body of knowledge pertaining to ASCT in MM in the African continent.
- 11 April 2025
- Published by AOSIS in South African Journal of Oncology
- Vol. 9, 8
Open AccessAutologous stem cell transplantation in multiple myeloma at Chris Hani Baragwanath Academic Hospital
Background: Autologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma (MM), even in the era of novel therapeutic agents. Data regarding ASCT outcomes in MM is lacking in South Africa. Aim: To assess the impact of ASCT on MM at a public health facility. Setting: Clinical Haematology Unit, Chris Hani Baragwanath Academic Hospital, Johannesburg. Methods: A retrospective analysis of MM patients who received ASCT over 19 years. Results: Fifty-one patients received ASCT as part of their treatment schedule. While 41 patients received a single transplantation, 10 patients underwent a salvage transplantation after relapsing. Most of the patients (74.5%) had a delayed transplantation. The median overall survival (OS) was 57 months for the entire group, 32 months in the early transplantation group and 58.5 months in the delayed transplantation group, with no statistical difference between the early and delayed groups (p = 0.12) and among the different International Staging System groups (p = 0.71). The median time for disease relapse after the first ASCT was 30 months. Conclusion: Autologous stem cell transplantation is an important consolidation treatment modality for MM in the South African public health sector as it prolongs survival. Greater access to novel agents during induction and relapse is advocated in the South African public health sector to further improve the outcomes that are currently seen with ASCT. Contribution: This study adds to the limited body of knowledge pertaining to ASCT in MM in the African continent.
- Open Access
- 1 January 2025
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 3 (1) , 7
Primary central nervous system lymphomas at a tertiary academic hospital in Johannesburg
Background: Primary central nervous system lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL), which affect multiple regions of the neuroaxis, including the brain parenchyma, the orbits, cranial nerves and leptomeninges, without systemic disease. The aim of this study was to review the clinical characteristics as well as the outcome of patients referred to a tertiary academic hospital in Johannesburg (South Africa) with a presumed PCNSL diagnosis based on histology, cerebrospinal fluid (CSF) analysis and neuroimaging. Methods: This retrospective record review at a tertiary academic hospital in Soweto (Johannesburg), included patients aged ≥ 17 years referred with a presumed diagnosis of PCNSL, based on biopsy-confirmed PCNSL, CSF analysis or neuroimaging, between January 2010 and December 2022. Patient characteristics (laboratory, clinical, treatment(s), outcome) were analysed in three groups based on diagnostic certainty for PCNSL (diagnostic, suspicious, consistent). Results: The cohort comprised 14 patients, with most cases occurring in People Living with Human Immunodeficiency Virus (PLWH) (n = 10; 71%), with equal representation of male and female patients. The median age of diagnosis was 43 years (17–64), with PLWH diagnosed at an earlier mean age of 40 compared to human immunodeficiency virus (HIV)-negative patients (mean age 52). Both surviving patients received between 6 and 8 cycles of high-dose methotrexate (HD-MTX), with one receiving an autologous stem cell transplant. Over half (57%) of the cohort died with a median overall survival of two months (95% CI 1.3–2.6). Conclusion: Establishing a PCNSL diagnosis without histology often relies on several ancillary investigations. The high mortality and poor median survival highlight the importance of timely diagnosis and treatment. Contribution: This case series highlights the the complexities of a PCNSL diagnosis in PLWH and will hopefully inspire future work in this area.
- 1 January 2025
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 3 (1) , 7
Open AccessPrimary central nervous system lymphomas at a tertiary academic hospital in Johannesburg
Background: Primary central nervous system lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL), which affect multiple regions of the neuroaxis, including the brain parenchyma, the orbits, cranial nerves and leptomeninges, without systemic disease. The aim of this study was to review the clinical characteristics as well as the outcome of patients referred to a tertiary academic hospital in Johannesburg (South Africa) with a presumed PCNSL diagnosis based on histology, cerebrospinal fluid (CSF) analysis and neuroimaging. Methods: This retrospective record review at a tertiary academic hospital in Soweto (Johannesburg), included patients aged ≥ 17 years referred with a presumed diagnosis of PCNSL, based on biopsy-confirmed PCNSL, CSF analysis or neuroimaging, between January 2010 and December 2022. Patient characteristics (laboratory, clinical, treatment(s), outcome) were analysed in three groups based on diagnostic certainty for PCNSL (diagnostic, suspicious, consistent). Results: The cohort comprised 14 patients, with most cases occurring in People Living with Human Immunodeficiency Virus (PLWH) (n = 10; 71%), with equal representation of male and female patients. The median age of diagnosis was 43 years (17–64), with PLWH diagnosed at an earlier mean age of 40 compared to human immunodeficiency virus (HIV)-negative patients (mean age 52). Both surviving patients received between 6 and 8 cycles of high-dose methotrexate (HD-MTX), with one receiving an autologous stem cell transplant. Over half (57%) of the cohort died with a median overall survival of two months (95% CI 1.3–2.6). Conclusion: Establishing a PCNSL diagnosis without histology often relies on several ancillary investigations. The high mortality and poor median survival highlight the importance of timely diagnosis and treatment. Contribution: This case series highlights the the complexities of a PCNSL diagnosis in PLWH and will hopefully inspire future work in this area.
- Open Access
- 24 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 211-224
Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study
B-HOLISTIC was a real-world, retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa. Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or relapsed/refractory HL (RRHL) from January 2010-December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Overall, 694 patients (RRHL: n=178; frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP) in Saudi Arabia (78.3%) and dexamethasone, cytarabine, cisplatin (DHAP) in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1- 10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively. This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. Additionally, these data may serve as a control group for future studies in these countries and inform clinical decision-making.
- 24 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 211-224
Open AccessTreatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study
B-HOLISTIC was a real-world, retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa. Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or relapsed/refractory HL (RRHL) from January 2010-December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Overall, 694 patients (RRHL: n=178; frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP) in Saudi Arabia (78.3%) and dexamethasone, cytarabine, cisplatin (DHAP) in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1- 10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively. This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. Additionally, these data may serve as a control group for future studies in these countries and inform clinical decision-making.
- 20 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (12) , 2192-2198
Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men
Background: Both multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS), occur twice as often within Black compared with White populations, suggesting that racial disparities lie within the development of MGUS. Nonetheless, MGUS has been studied mainly in White cohorts; the study that first described the natural history of MGUS was conducted in 97.3% White Olmsted County, Minnesota. Methods: We determined the prevalence of MGUS among 386 Black South African (SA) men >30 years at Chris Hani Baragwanath Hospital in Johannesburg. We conducted serum protein electrophoresis and free light chain quantification to define MGUS by the same criteria as the Olmsted County studies. We also investigated the association between MGUS and various clinical factors, including human immunodeficiency virus (HIV) infection and smoking. Results: We found the prevalence of MGUS to be 8.03% [95% confidence interval (CI), 5.32–10.74], nearly 1.6-fold higher than in the White Olmsted County male population. In a univariable logistic regression model, MGUS was associated with HIV status (OR, 2.39; 95% CI, 0.95–5.49), but in an adjusted model that included body mass index and cigarette use, the association was not statistically significant. Those who were current (vs. never) cigarette smokers were more likely to have MGUS in both univariable (OR, 5.60; 95% CI, 2.16–17.42) and multivariable models (OR, 4.49; 95% CI, 1.63–14.56). Conclusions: The prevalence of MGUS in Black SA men is substantially higher than in White populations and may be associated with HIV status and cigarette use. Impact: Racial disparities in MGUS exist and may be associated with potentially modifiable risk factors.
- 20 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (12) , 2192-2198
Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men
Background: Both multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS), occur twice as often within Black compared with White populations, suggesting that racial disparities lie within the development of MGUS. Nonetheless, MGUS has been studied mainly in White cohorts; the study that first described the natural history of MGUS was conducted in 97.3% White Olmsted County, Minnesota. Methods: We determined the prevalence of MGUS among 386 Black South African (SA) men >30 years at Chris Hani Baragwanath Hospital in Johannesburg. We conducted serum protein electrophoresis and free light chain quantification to define MGUS by the same criteria as the Olmsted County studies. We also investigated the association between MGUS and various clinical factors, including human immunodeficiency virus (HIV) infection and smoking. Results: We found the prevalence of MGUS to be 8.03% [95% confidence interval (CI), 5.32–10.74], nearly 1.6-fold higher than in the White Olmsted County male population. In a univariable logistic regression model, MGUS was associated with HIV status (OR, 2.39; 95% CI, 0.95–5.49), but in an adjusted model that included body mass index and cigarette use, the association was not statistically significant. Those who were current (vs. never) cigarette smokers were more likely to have MGUS in both univariable (OR, 5.60; 95% CI, 2.16–17.42) and multivariable models (OR, 4.49; 95% CI, 1.63–14.56). Conclusions: The prevalence of MGUS in Black SA men is substantially higher than in White populations and may be associated with HIV status and cigarette use. Impact: Racial disparities in MGUS exist and may be associated with potentially modifiable risk factors.
- 10 February 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 58, 151913
HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies
- 10 February 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 58, 151913
HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 611-621
Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma
PURPOSE: Diagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. Assessment of plasma cell-free DNA (cfDNA) by next-generation sequencing (NGS) may expedite the diagnosis of lymphoma but requires high-quality cfDNA.METHODS: People living with HIV with newly diagnosed aggressive B-cell lymphoma and those with newly diagnosed TB seeking care at Chris Hani Baragwanath Academic Hospital and its surrounding clinics, in Soweto, South Africa, were enrolled in this study. Each participant provided a whole blood specimen collected in cell-stabilizing tubes. Quantity and quality of plasma cfDNA were assessed. NGS of the immunoglobulin heavy chain was performed.RESULTS: Nine HIV+ patients with untreated lymphoma and eight HIV+ patients with TB, but without lymphoma, were enrolled. All cfDNA quantity and quality metrics were similar between the two groups, except that cfDNA accounted for a larger fraction of recovered plasma DNA in patients with lymphoma. The concentration of cfDNA in plasma also trended higher in patients with lymphoma. NGS of immunoglobulin heavy chain showed robust amplification of DNA, with large amplicons (> 250 bp) being more readily detected in patients with lymphoma. Clonal sequences were detected in five of nine patients with lymphoma, and none of the patients with TB.CONCLUSION: This proof-of-principle study demonstrates that whole blood collected for cfDNA in a low-resource setting is suitable for sophisticated sequencing analyses, including clonal immunoglobulin NGS. The detection of clonal sequences in more than half of patients with lymphoma shows promise as a diagnostic marker that may be explored in future studies.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 611-621
Open AccessFeasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma
PURPOSE: Diagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. Assessment of plasma cell-free DNA (cfDNA) by next-generation sequencing (NGS) may expedite the diagnosis of lymphoma but requires high-quality cfDNA.METHODS: People living with HIV with newly diagnosed aggressive B-cell lymphoma and those with newly diagnosed TB seeking care at Chris Hani Baragwanath Academic Hospital and its surrounding clinics, in Soweto, South Africa, were enrolled in this study. Each participant provided a whole blood specimen collected in cell-stabilizing tubes. Quantity and quality of plasma cfDNA were assessed. NGS of the immunoglobulin heavy chain was performed.RESULTS: Nine HIV+ patients with untreated lymphoma and eight HIV+ patients with TB, but without lymphoma, were enrolled. All cfDNA quantity and quality metrics were similar between the two groups, except that cfDNA accounted for a larger fraction of recovered plasma DNA in patients with lymphoma. The concentration of cfDNA in plasma also trended higher in patients with lymphoma. NGS of immunoglobulin heavy chain showed robust amplification of DNA, with large amplicons (> 250 bp) being more readily detected in patients with lymphoma. Clonal sequences were detected in five of nine patients with lymphoma, and none of the patients with TB.CONCLUSION: This proof-of-principle study demonstrates that whole blood collected for cfDNA in a low-resource setting is suitable for sophisticated sequencing analyses, including clonal immunoglobulin NGS. The detection of clonal sequences in more than half of patients with lymphoma shows promise as a diagnostic marker that may be explored in future studies.
- Open Access
- 1 January 2021
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 3 (1)
Evolving Changes in the Full Blood Count in Tuberculosis
Background: Changes in the full blood count of patients with tuberculosis have been studied previously, but the effect of co-infection with human immunodeficiency virus (HIV) remains to be explored. Objective: To evaluate the changes in full blood count in patients with tuberculosis in an evolving HIV era. Methods: Prospective study of consecutively recruited patients (N = 125) with microbiologically or histologically proven tuberculosis admitted at Chris Hani Baragwanath Academic Hospital between October 2017 and July 2018. Results: Anaemia was found in 60.7% of patients with pulmonary tuberculosis (PTB) and in 61.1% of extra-pulmonary tuberculosis (ETB) patients. ETB patients had lower white cell counts (WCCs) and lower neutrophil counts than PTB patients, (5.59 (3.6–8.1) vs 7.96 (5.27–10.34), p = 0.002) and (4.2 (2.1–7.0) vs 5.5 (3.3–8.4), p = 0.079), respectively. Compared to the HIV-seronegative patients, HIV co-infected PTB patients had lower WCC, lymphocyte counts and neutrophil counts, (6.9 (4.8–9.7) vs 9.4 (8.6–11.4), p = 0.0037), (0.7 (0.46–1.31) vs 1.51 (1.13–2.05), p = 0.0051), and (4.7 (2.8–7.7) vs 8.5 (5.9–10.1), p = 0.0106), respectively. Patients co-infected with HIV on combination antiretroviral therapy and tuberculosis had higher levels of WCC, (7.9 (4.6–10.9) vs 5.8 (4.3–8.3), p = 0.0465). Conclusion: Anaemia is the most common manifestation of tuberculosis. This study highlighted the reactive nature of PTB haematological abnormalities compared to ETB with higher WCCs in both HIV-seropositive and HIV-seronegative patients. Co-infection with HIV was associated with blunting of some of the previously described haematological manifestations among patients with PTB.
- 1 January 2021
- Published by Wits University Press in Wits Journal of Clinical Medicine
- Vol. 3 (1)
Open AccessEvolving Changes in the Full Blood Count in Tuberculosis
Background: Changes in the full blood count of patients with tuberculosis have been studied previously, but the effect of co-infection with human immunodeficiency virus (HIV) remains to be explored. Objective: To evaluate the changes in full blood count in patients with tuberculosis in an evolving HIV era. Methods: Prospective study of consecutively recruited patients (N = 125) with microbiologically or histologically proven tuberculosis admitted at Chris Hani Baragwanath Academic Hospital between October 2017 and July 2018. Results: Anaemia was found in 60.7% of patients with pulmonary tuberculosis (PTB) and in 61.1% of extra-pulmonary tuberculosis (ETB) patients. ETB patients had lower white cell counts (WCCs) and lower neutrophil counts than PTB patients, (5.59 (3.6–8.1) vs 7.96 (5.27–10.34), p = 0.002) and (4.2 (2.1–7.0) vs 5.5 (3.3–8.4), p = 0.079), respectively. Compared to the HIV-seronegative patients, HIV co-infected PTB patients had lower WCC, lymphocyte counts and neutrophil counts, (6.9 (4.8–9.7) vs 9.4 (8.6–11.4), p = 0.0037), (0.7 (0.46–1.31) vs 1.51 (1.13–2.05), p = 0.0051), and (4.7 (2.8–7.7) vs 8.5 (5.9–10.1), p = 0.0106), respectively. Patients co-infected with HIV on combination antiretroviral therapy and tuberculosis had higher levels of WCC, (7.9 (4.6–10.9) vs 5.8 (4.3–8.3), p = 0.0465). Conclusion: Anaemia is the most common manifestation of tuberculosis. This study highlighted the reactive nature of PTB haematological abnormalities compared to ETB with higher WCCs in both HIV-seropositive and HIV-seronegative patients. Co-infection with HIV was associated with blunting of some of the previously described haematological manifestations among patients with PTB.
- 1 February 2019
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 58 (1) , 43-47
Assessment of the knowledge of usage of blood and blood products amongst medical doctors in the Department of Medicine at the Faculty of Health Sciences, University of the Witwatersrand affiliated academic hospitals
- 1 February 2019
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 58 (1) , 43-47
Assessment of the knowledge of usage of blood and blood products amongst medical doctors in the Department of Medicine at the Faculty of Health Sciences, University of the Witwatersrand affiliated academic hospitals
- 1 November 2015
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 34 (6) , 564-569
An Expanded Spectrum of High-Grade B-Cell Non-Hodgkin Lymphomas Involving the Cervicovaginal Region
The uterine cervix and vaginal regions are infrequently infiltrated by lymphoma. Involvement of these topographic regions may constitute primary disease or more commonly represent a manifestation of systemic lymphomatous disease. Herein, we report an expanded spectrum of high-grade B-cell non-Hodgkin lymphomas comprising plasmablastic lymphoma (with and without plasmacytic differentiation), ALK-positive large B-cell lymphoma, and diffuse large B-cell lymphoma which involved the uterine cervix and/or vagina of 6 patients at initial diagnosis. These tumors clinically mimicked carcinoma and developed predominantly, but not exclusively, in the setting of human immunodeficiency virus infection.
- 1 November 2015
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 34 (6) , 564-569
An Expanded Spectrum of High-Grade B-Cell Non-Hodgkin Lymphomas Involving the Cervicovaginal Region
The uterine cervix and vaginal regions are infrequently infiltrated by lymphoma. Involvement of these topographic regions may constitute primary disease or more commonly represent a manifestation of systemic lymphomatous disease. Herein, we report an expanded spectrum of high-grade B-cell non-Hodgkin lymphomas comprising plasmablastic lymphoma (with and without plasmacytic differentiation), ALK-positive large B-cell lymphoma, and diffuse large B-cell lymphoma which involved the uterine cervix and/or vagina of 6 patients at initial diagnosis. These tumors clinically mimicked carcinoma and developed predominantly, but not exclusively, in the setting of human immunodeficiency virus infection.